NEW YORK (GenomeWeb) – N-of-One has entered into a partnership to help Agena Bioscience interpret cancer genomic data generated by its MassArray system, the companies announced today.
Agena’s MassArray is a research-use-only platform designed to detect genetic variation with end-point PCR and label-free mass spectrometry. The deal with N-of-One is designed to support the expansion of MassArray Insights, a recently launched reporting network through which Agena seeks to collaborate with various molecular analysis platform providers.
“MassArray Insights is part of Agena Bioscience’s continued effort to support our CLIA-high complexity certified lab customers who are tackling the challenges presented in molecular diagnostics,” Agena CEO Pete Dansky said in a statement. “We are happy to partner with … N-of-One to help bring our lab clients an important component that nicely follows the value of our test: an evidence-based, clinically actionable report.”
Specific terms of the deal were not disclosed.
In September, Agena signed on Molecular Health as the first interpretation software provider for MassArray Insights.